|
1. Biologie
|
|
|
Study signals a limit to cancer’s complexity [Harvard Gazette]
|
|
|
|
|
|
“Most
cancer studies analyze the primary tumor,” Reiter said. “There are not
many cases where we have genetic information from the primary tumor and
several metastases and moreover in patients that have not been treated
with chemotherapy. Such treatment could induce many additional
mutations.”
|
|
|
|
|
|
|
|
3.1 Prévention - Tabac
|
|
|
|
3.1.1 Prévention - Tabac - e-cigs
|
|
|
|
|
4.1 Dép., diag. & prono. - Prostate
|
|
|
|
4.12 Biopsies liquides
|
|
|
Blood Test Identifies More Treatable Cancer Mutations Than Tissue Biopsy Alone [Penn Medicine]
|
|
|
|
|
|
“Solid
tissue biopsy is still essential for accurate diagnosis, but we’ve now
shown liquid biopsy can add value when it’s used additionally, and also
that it can serve as a viable alternative when solid biopsies aren’t
feasible,” Carpenter said. “Given how rapidly targeted therapies are
evolving, this is something that should be routinely incorporated into
standard of care.”
|
|
|
|
|
|
|
4.2 Dép., diag. & prono. - Génome
|
|
|
|
|
4.9 Dép., diag. & prono. - Sein
|
|
|
|
|
5.12.4 Immunothérapies - Essais
|
|
|
|
|
|
|
|
5.2 Pharma
|
|
|
|
5.3 Traitements - FDA, EMA, NICE...
|
|
|
MHRA Offers Guidance for Trials in Event of ‘No-Deal’ Brexit [RAPS]
|
|
|
|
|
|
“Clinical
Trials that use IMPs which come from or via the EU/EEA will need to
ensure appropriate arrangements to assure supplies in the event of any
possible border delays that may arise in the short term in the unlikely
event of a no-deal Exit,” the guidance says. The regulator also advises
companies to start making contingency arrangements to provide assurances
for the trials and participants.
|
|
|
|
|
|